US 12,234,261 B2
Hepatitis B vaccines and uses of the same
Douglas E. Brough, Germantown, MD (US); Cheryl G. Bolinger, Germantown, MD (US); Ramya Yarlagadda, Germantown, MD (US); Vinodhbabu Kurella, Germantown, MD (US); Prabakaran Ponraj, Germantown, MD (US); Simon Metenou, Germantown, MD (US); and Kuan-Fu Ding, Germantown, MD (US)
Assigned to Precigen, Inc., Germantown, MD (US)
Filed by Precigen, Inc., Germantown, MD (US)
Filed on Dec. 2, 2022, as Appl. No. 18/074,302.
Application 18/074,302 is a continuation of application No. 16/978,570, granted, now 11,608,362, previously published as PCT/US2019/020930, filed on Mar. 6, 2019.
Claims priority of provisional application 62/639,354, filed on Mar. 6, 2018.
Prior Publication US 2023/0279057 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/29 (2006.01); A61K 39/12 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 14/02 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); C12N 15/861 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61K 39/292 (2013.01); A61K 48/0066 (2013.01); C07K 14/02 (2013.01); C12N 7/00 (2013.01); C12N 15/861 (2013.01); C07K 2319/33 (2013.01); C12N 2710/20022 (2013.01); C12N 2710/20034 (2013.01)] 16 Claims
 
1. A polypeptide construct comprising:
(a) (i) an HBV Pol domain consisting of SEQ ID NO: 99, and (ii) at least one additional domain selected from: an HBV Envelope domain consisting of SEQ ID NO: 100; an HBV Core domain consisting of SEQ ID NO: 101; and an HBx domain consisting of SEQ ID NO: 98; or
(b) (i) an ankyrin-like repeat domain, and (ii) an HBV polypeptide.